Werewolf Therapeutics (NASDAQ:HOWL) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL) to a sell rating in a report issued on Saturday.

Separately, Weiss Ratings downgraded shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Trading Down 29.4%

Shares of NASDAQ HOWL opened at $0.35 on Friday. Werewolf Therapeutics has a 12 month low of $0.27 and a 12 month high of $2.38. The firm has a market capitalization of $17.16 million, a PE ratio of -0.46 and a beta of 0.30. The firm has a fifty day simple moving average of $0.39 and a two-hundred day simple moving average of $0.60.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Friday, July 31st. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.36. The company had revenue of $21.00 million during the quarter. On average, sell-side analysts predict that Werewolf Therapeutics will post -1.08 earnings per share for the current year.

Insider Transactions at Werewolf Therapeutics

In other news, Director Luke Evnin sold 107,429 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total transaction of $145,918.85. Following the sale, the insider owned 303,719 shares in the company, valued at approximately $106,301.65. The trade was a 57.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 3,634,670 shares of company stock valued at $1,751,888. 23.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC lifted its position in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $48,000. AQR Capital Management LLC purchased a new position in shares of Werewolf Therapeutics in the first quarter worth $79,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.